Biliary epithelial‐mesenchymal transition in posttransplantation recurrence of primary biliary cirrhosis†‡
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
UNLABELLED: Primary biliary cirrhosis (PBC) recurs in the allograft after liver transplantation. Study of early tissue changes in the time-course of disease recurrence provides a unique insight into the initial stages of the disease process, which, in nontransplant patients, occurs long before clinical presentation. We describe a patient who developed classical clinical, biochemical, immunological, and histological features of PBC within 9 months after transplantation. Use of tissue from this patient before and during the development of PBC allowed us to identify biliary epithelial cell (BEC) epithelial-mesenchymal transition (EMT) as a key pathogenetic process. BEC expression of S100A4 (an early fibroblast lineage marker established as a robust marker of EMT), vimentin, and pSmad 2/3 [a marker of transforming growth factor beta (TGF-beta) pathway signaling] were identified immunohistochemically in most BECs in liver tissue from this patient at the point of diagnosis of recurrent disease. BEC expression of S100A4 and pSmad 2/3 was seen as early as 24 days after orthotopic liver transplantation (OLT), although no other features of recurrent PBC were present at this time. CONCLUSION: S100A4, vimentin, and pSmad 2/3 expression in early recurrent PBC after OLT suggests that BEC EMT is occurring (potentially explaining BEC loss) and that this process is driven by TGF-beta. S100A4 expression by BEC appears to occur before the development of any other features of recurrent PBC, suggesting that EMT may be an initiating event.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kaplan, M. M., & Gershwin, M. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043898 · Cited by 1,144
Cited by
Kisseleva, T., & Brenner, D. A. (2008) · Experimental Biology and Medicine · doi:10.3181/0707-mr-190 · Cited by 503
Richardson, M. M., Jonsson, J. R., Powell, E. E., Brunt, E. M., Neuschwander–Tetri, B. A., Bhathal, P. S., Dixon, J. B., Weltman, M. D., Tilg, H., Moschen, A. R., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.012 · Cited by 482
Omenetti, A., Porrello, A., Jung, Y., Yang, L., Popov, Y., Choi, S. S., Witek, R. P., Alpini, G., Venter, J., Vandongen, H. M., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35875 · Cited by 341
Fibroblast-specific protein 1 identifies an inflammatory subpopulation of macrophages in the liver
Österreicher, C. H., Penz-Österreicher, M., Grivennikov, S. I., Guma, M., Koltsova, E. K., Datz, C., Sasik, R., Hardiman, G., Karin, M., & Brenner, D. A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017547108 · Cited by 337
Hepatocytes Do Not Undergo Epithelial-Mesenchymal Transition in Liver Fibrosis in Mice
Taura, K., Miura, K., Iwaisako, K., Österreicher, C. H., Kodama, Y., Penz-Österreicher, M., & Brenner, D. A. (2010) · Hepatology · doi:10.1002/hep.23368 · Cited by 336
Connective tissue growth factor: a fibrogenic master switch in fibrotic liver diseases
Gressner, O. A., & Gressner, A. M. (2008) · Liver International · doi:10.1111/j.1478-3231.2008.01826.x · Cited by 270
Wallace, K., Burt, A. D., & Wright, M. C. (2008) · Biochemical Journal · doi:10.1042/bj20071570 · Cited by 262
Self-citationDirect contribution of epithelium to organ fibrosis: epithelial-mesenchymal transition
Guarino, M., Tosoni, A., & Nebuloni, M. (2009) · Human Pathology · doi:10.1016/j.humpath.2009.02.020 · Cited by 253
Cellular Mechanisms of Liver Fibrosis
Acharya, P., Chouhan, K., Weiskirchen, S., & Weiskirchen, R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.671640 · Cited by 252
Cannito, S., Novo, E., di Bonzo, L. V., Busletta, C., Colombatto, S., & Parola, M. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2737 · Cited by 239
“Moreover, EMT of BDEC was also described in post-transplantation recurrence of PBC (219).”
InfluentialDrug targeting to myofibroblasts: Implications for fibrosis and cancer
Yazdani, S., Bansal, R., & Prakash, J. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.07.010 · Cited by 189
“ithelial cells (hepatocytes and cholangiocytes) has also been suggested to actively participate in liver fibrosis [23,24], recent in vivo cell fatemapping studies negated these findings [25–27].”
ResultDrug targeting to the diseased liver
Poelstra, K., Prakash, J., & Beljaars, L. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.02.011 · Cited by 172
“Bile duct epithelial cells play a key role in the pathogenesis of several hepatic diseases [5].”
BackgroundCyclosporine A Protects Against Primary Biliary Cirrhosis Recurrence After Liver Transplantation
Montano, A. J., Wasilenko, S., Bintner, J., & Mason, A. L. (2010) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.03006.x · Cited by 99
Nakanuma, Y., Zen, Y., & Portmann, B. C. (2012) · MacSween's Pathology of the Liver · doi:10.1016/b978-0-7020-3398-8.00010-6 · Cited by 56
Chobert, M.-N., Couchie, D., Fourcot, A., Zafrani, E.-S., Laperche, Y., Mavier, P., & Brouillet, A. (2012) · Laboratory Investigation · doi:10.1038/labinvest.2011.143 · Cited by 44
The Matrisome, Inflammation, and Liver Disease
Dolin, C. E., & Arteel, G. E. (2020) · Seminars in Liver Disease · doi:10.1055/s-0039-3402516 · Cited by 38
Huang, Q., Chu, S., Yin, X., Yu, X., Kang, C., Li, X., & Qiu, Y. (2016) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.240.269 · Cited by 29
Berglin, L., Björkström, N. K., & Bergquist, A. (2013) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2013.786131 · Cited by 15
“to occur in vivo in a number of chronic inflammatory liver diseases [12,13], including PSC [14].”
Background
Metadata
- Authors
- Robertson, H., Kirby, J. A., Yip, W. W., Jones, D. E. J., & Burt, A. D.
- Venue
- Hepatology
- Published
- 2007-04
- Volume
- 45
- Issue
- 4
- Pages
- 977-981
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1984211346
- Cited by
- 149
- References
- 1
- FWCI
- 12.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.